A novel assay for monitoring the activity of the bacterial enzyme UDP-N-acetylmuramyl-l-alanine:d-glutamate ligase (MurD ligase) is presented. MurD, which belongs to an enzyme family of Mur ligases, is essential for the synthesis of bacterial peptidoglycan and therefore represents an attractive target for the discovery of novel antibacterial agents. The inhibition assay described in this article is amenable to high-throughput screening. It is based on the detection of the accumulation of adenosine 5′-diphosphate (ADP), a product of the reaction catalyzed by MurD ligase, by conversion to a fluorescent signal via a coupled enzyme system, using the ADP Quest assay kit from DiscoveRx. The novel assay has been validated by obtaining K M,app values for substrates d-Glu, UDP-N-acetylmuramyl-l-alanine (UMA) and ATP that are in agreement with the data reported in the literature. A counterscreen assay was introduced to eliminate false positives, and some of the known MurD inhibitors have been retested to compare the data measured with different methods. Moreover, a focused library of around 1000 compounds was screened for the inhibition of MurD to assess the performance and robustness of the assay. Finally, a novel MurD inhibitor belonging to a new structural class, with an IC 50 value of 105 µM, was discovered. (Journal of Biomolecular Screening 2009:412-418) 
INTRODUCTION

T
he increasing emergence of pathogenic bacterial strains with high resistance to antibiotic therapy constitutes a serious public threat. This has underlined an urgent need for the discovery of novel effective antibacterial agents directed toward previously unexploited targets. 1 Peptidoglycan is an essential cell wall polymer unique to prokaryotic cells that provides the rigidity, flexibility, and strength required for bacterial cells to grow and divide while withstanding high internal osmotic pressure, therefore representing an optimal target with respect to selective toxicity. The Mur ligases (MurC-F) catalyze the assembly of the peptide moiety of bacterial peptidoglycan and have gained importance as potential targets in antibacterial research over the past years. 2 These adenosine triphosphate (ATP)-dependent enzymes, which are presumably essential for the bacteria, catalyze a series of reactions leading from the MurC substrate UDP-N-acetylmuramic acid (UDP-MurNAc or UNAM) to the completed UDPMurNAc-pentapeptide by sequentially adding l-Ala (MurC), d-Glu (MurD), meso-diaminopimelic acid or l-Lys (MurE), and d-Ala-d-Ala dipeptide (MurF) to the UDP-MurNAc. Mur ligases most likely operate by an essentially similar mechanism. 1 After the initial phosphorylation of the terminal carboxyl group of the UDP-substrate, the resulting acyl-phosphate is attacked by the amine moiety of the condensing amino acid residue. The tetrahedral transition state intermediate produced thereafter subsequently collapses to yield amide, adenosine diphosphate (ADP), and inorganic phosphate. [3] [4] [5] [6] [7] [8] The main point of our interest has been MurD, the second in the series of Mur ligases that catalyzes the addition of d-glutamic acid to the cytoplasmic intermediate UDP-MurNAc-l-Ala (UMA; Fig. 1 ). Up to now, several different approaches have been used to monitor the d-glutamate-adding enzyme activity.
The first is the radiometric assay, which measures the production of the radioactive product UDP-MurNAc-l-Ala-dGlu (UMAG) using radioactive UDP-MurNAc-l-[
14 C]Ala 9 or d-[
14 C]Glu. 10, 11 Because radioactive isotopes allow a specific labeling of a single atom of a substrate, these assays are both extremely sensitive and specific. However, due to the radioactive substrates/product, such assays are not very appropriate for implementation to a high-throughput screening (HTS) format. Moreover, the labware and reagents have to be handled with great caution. Two other protocols have been adapted to a 96-well microplate format to allow parallel runs of multiple assays and eliminate the use of the radioactive tracer. One of the protocols follows spectrophotometrically (absorbance at 660 nm) the formation of orthophosphate generated during the reaction by adding a malachite green-molybdate reagent 11 or a commercially available BioMol Green reagent 12, 13 to an aliquot of a reaction mixture at several designated time points because the reaction stops after the addition of the reagent. It has also been described that this assay can give false results due to the interference of a P i signal by the compounds (signal attenuation or enhancement).
14 Also, a decrease in absorbance values with longer times has been observed due to the precipitation of the malachite green dye. For the processing of multiple plates in an HTS format, such events could potentially cause misleading results. 14 The third protocol takes advantage of the change of absorbance at 340 nm over time by coupling the MurD reaction with a significant excess of pyruvate kinase, lactate dehydrogenase, phosphoenolpyruvate, and NADH. This protocol monitors the ADP formation in the MurD-catalyzed reaction in a continuous assay. 11 When compared to the other assays described above, this is a continuous assay. Data in the continuous assay are collected in real time and allow the rapid determination of true initial rates (linear product formation). Behavior of progress curves also allows immediate inferences concerning the nature of the inhibition event for novel inhibitors. However, this assay requires monitoring of the product NADH by absorbance at a wavelength susceptible to compound interference. Moreover, the assay signal may be affected by a significant signal drift due to the decomposition of NADH induced by UV light. 15 In contrast to recently developed ADP-antibody based assay kits, which can be highly resistant to compound interference ( 16 but to our knowledge, this is the first time this approach has been applied to Mur ligases.
MATERIALS AND METHODS
Materials
ATP, β,γ-methyleneadenosine 5′-triphosphate (AMP-PCP), d-Glu, and all other reagents were of reagent grade or ultra pure and purchased from Sigma-Aldrich (St. Louis, MO). Substrate UMA was enzymatically synthesized from UNAM 17 and purified in a similar way as described previously. 18 Compound 1 was prepared as described elsewhere, 19 whereas compound 2 was purchased from a commercially available Asinex Gold (www.asinex.com) compound collection.
The ADP Quest assay kit was obtained from DiscoveRx Corp (Fremont, CA). It is composed of ADP reagent A (50 mM phosphate buffer, pH 7.0, 250 µM Amplex Red and 1 U/ml catalase), ADP reagent B (50 mM phosphate buffer [pH 7.0], 2.5 mM MgCl 2 , 25 µM flavine adenine dinucleotide, 250 µM thiamine pyrophosphate, 250 µM PEP, 25 U/mL horseradish peroxidase, 50 U/mL pyruvate kinase, 15 U/mL pyruvate oxidase, and 1 U/mL catalase), ADP standard (225 µM), and assay buffer (15 mM HEPES, 20 mM NaCl, 1 mM EGTA, 0.02% Tween-20, 10 mM MgCl 2 , 0.1% bovine γ-globulins, pH 7.4).
The recombinant Escherichia coli MurD ligase was overexpressed and purified using the 6× His-tag system as reported earlier. 10, 20 The amount of protein obtained was determined by the Bradford method, a quantitative amino acid analysis, and by measuring the absorbance at 280 nm. The purity of the protein was checked by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass spectrometry, and the protein was >95% pure. Aliquots in 10% glycerol were frozen and stored at -80 °C for further use.
In addition, 96-well black polystyrene flat-bottomed (normal and half-area) assay plates were purchased from Greiner BioOne (Monroe, NC), and 96-well, transparent U-bottomed plates were obtained from Starlab (Ahrensburg, Germany).
Determination of K M,app for d-Glu, UMA, and ATP
All K M,app values were determined on a Tecan Safire plate reader in 100-µL volumes, using black 96-well flat-bottomed plates. The determination of K M,app for each substrate was performed under saturating conditions of the other 2 substrates. Similarly, UMA and ATP dependency studies were performed, using serially diluted UMA (1-50 µM) and ATP (10-250 µM), respectively, with 2 other substrates at 200 µM (all final concentration). The initial rates for the reaction were determined from the linear part of the progress curves. Data were analyzed using GraphPad Prism software (Version 4.03, GraphPad Software, San Diego, CA).
Assay conditions
For the purpose of the HTS format, a Freedom Evo robotic platform, equipped with an 8-tip liquid-handling arm, robotic arm, shaker, incubator, and an Infinite F200 plate reader (Tecan, Mannedorf, Switzerland), was used for the automation of the assay.
The assay was programmed on Freedom EVO using EVOware  Standard software. First, dilution plates for screening (100 and 20 µM) were prepared in DMSO from the original DMSO stock solution and later directly transferred into an assay buffer, thus preventing the chance of misleading screening and IC 50 results due to compound insolubility in the buffer at higher concentrations. To eliminate the formation of aggregates that associate with enzyme molecules and nonspecifically inhibit their activity, [21] [22] [23] we used a nonionic detergent, Tween-20, in a subcritical micellar concentration (final concentration around 0.005%) in the assay media.
The ATP, enzyme, reagent A, reagent B, and compounds in triplicate (one of the replicates was used for background correction) were added to the assay plate (96-well black polystyrene flat-bottomed half-area). In addition, 6 wells contained only DMSO and 6 wells contained AMP-PCP (final concentration 500 µM) for the full reaction rate and positive hit control, respectively. All the components were well mixed in a combined microplate incubator/shaker at 37 ºC for 5 min. In the last step, a substrate solution (UMA and d-Glu) or d-Glu (background rate) was added to initiate the reaction. Final concentrations in the wells were as follows: 100 µM ATP, 80 µM d-Glu, 20 µM (full rate) or 0 µM (background correction) UMA, and 30 nM enzyme in 60-µL volumes.
It has been found that 5% DMSO does not decrease MurD activity, and according to the manufacturer's instructions, 5% DMSO is also well below the acceptable limits for the components of the ADP Quest assay kit. Therefore, 5% DMSO was present in the assay to enhance the solubility of the tested compounds.
The assay plate was then immediately transferred to the Tecan Infinite 200F plate reader/shaker with a robotic arm, and the enzyme activity was continuously monitored every 2 min for 12 min at 37 ºC (530/590 nm for excitation/emission wavelengths).
The initial rates for the reaction were determined from the linear part of the progress curves. Data were analyzed using Microsoft Excel and GraphPad Prism software. The inhibition of MurD was determined by comparing the rates of each compound to the full reaction rate (with 5% DMSO), after subtracting the background rate: % Inhibition = 100 × [1 -(compound rate -background rate)/ (full reaction rate -background rate)].
The Z′ value was determined for the assay using DMSO instead of compounds, according to Zhang et al.
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Counterscreen assay
To confirm the specific inhibition against the MurD ligase and to exclude the inhibition against the other enzymes in the coupled assay, we tested the hits in a counterassay that was performed as above, except no MurD enzyme and ATP were added to the reaction mixture. Instead, only buffer and ADP (0.3 µM, final concentration) were added. For the purpose of this counterscreen, only the highest screening concentration of the compound (100 µM) was selected. Again, data were analyzed using Microsoft Excel and GraphPad Prism software as described above.
Determination of IC 50 values
IC 50 values were determined for compounds with a confirmed specific MurD inhibition mode as follows. Compound dilution plates for IC 50 determination (8 data points, 1:3 serial dilutions in DMSO, 500-0.2 µM) were made on Starlab polypropylene U-bottom 96-well plates from the original 10-mM DMSO stock solution in 1.5-mL tubes. Assays were performed as described in the previous section. The IC 50 curves were analyzed using GraphPad Prism software (variable Hill value, whereas top and bottom values were fixed at 100% and 0%, respectively).
RESULTS AND DISCUSSION
The assay described in this article is a generic, non-antibodybased, nonradioactive method to detect the amount of ADP produced as a result of enzyme activity (Fig. 1) . It is a coupledenzyme assay, involving pyruvate kinase, pyruvate oxidase, and peroxidase, that can translate the accumulation of ADP into a detectable resorufin signal. 16 Our initial experiment was to determine the linear range of ADP detection, and the ADP response was linear between 0.12 and 30 µM (data not shown). Then, all assay components (i.e., ATP, UMA, d-Glu, and the enzyme) were titrated to obtain optimal conditions. The enzyme concentration and the optimal reaction rate were determined in 100-µL reaction volumes in 96-well plates, with the enzyme concentration being adjusted to provide a linear reaction rate for 12 min. Different concentrations of the MurD enzyme were tested, and the 30-nM concentration was chosen for the assay. The stability of the enzyme was also checked and was stable in the buffer at 4 °C for a minimum of 3 h.
We have observed that ATP present in the reaction contributes to the assay background. The reason could be an eventual ADP contamination of the ATP stock solution. In addition, it has also been reported that Mur ligases possess minor phosphatase activity. 8 Therefore, ATP, the enzyme, and d-Glu were present in all background screens, giving the background rate that was later subtracted from the full reaction rate.
Determination of K M,app for d-Glu, UMA, and ATP
The utility of the coupled ADP Quest assay for inhibitor characterization was evaluated by the determination of the kinetic parameter K M,app for each E. coli MurD substrate. The K M,app for UMA was 7.3 µM and is also close to the values reported in the literature: 5 µM, 25 7.5 µM, 26 and 7 µM. 11 The K M,app for ATP determined with the ADP Quest assay kit was 106 µM, which is again in good agreement with the previously reported values for ATP K M : 60 µM, 25 138 µM, 26 and 135 µM.
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As for every enzymatic assay, one of the crucial factors to be considered are the concentrations of the substrates used. To ensure that inhibitor screening is performed in a way that is not biased toward a particular type of inhibitor with respect to its mode of inhibition, one should use substrate concentrations close to their K M values. 27 Consequently, substrate concentrations of 100 µM ATP, 80 µM d-Glu, and 20 µM UMA were chosen to not greatly exceed the K M values and at the same time retain a good signal-to-noise ratio in the assay.
Compound preincubation
Although it has not been proved for MurD yet, biochemical data for MurC and MurF suggest that Mur ligases bind ATP first. 28, 29 This is presumably followed by a conformational change, which "sets" the enzyme into an appropriate conformation for the acceptance of 2 other substrates. 3 Therefore, we have incubated the enzyme with the ATP, reagents A and B, and the inhibitor for 5 min at 37 °C prior to the addition of substrates UMA and d-Glu. We tested the stability of the enzyme in the reaction mixture at 37 °C, and no significant differences in enzyme activity were observed when compared to the samples without the preincubation. In addition, preincubation can also be used to investigate the possible slowbinding behavior of the inhibitors. Preincubation at 25 °C for 40 min had no significant impact on enzyme activity either.
To lower the chances of detecting false-positive hits that might interact with other enzymes in this coupled enzyme assay and not MurD specifically, we introduced a counterscreen. Screening was performed in the absence of the MurD enzyme and ATP, whereas ADP was added to the assay buffer.
Characterization of reference MurD inhibitors
Two compounds have been initially tested for further validation of the assay. Compound 1 (Fig. 3) is a glutamic acid derivative, a MurD inhibitor competitive against d-Glu with a K I value of 240 µM (IC 50 280 µM at 25 µM d-Glu). 19 Next, a nonhydrolyzable ATP analog, AMP-PCP, which is a competitive ATP inhibitor of MurC 14, 30 and MurF, 28 was investigated. Screening assays performed revealed that both compounds exhibited weak inhibition. Therefore, IC 50 values were determined by using 8 concentration points ranging from 500 to 3.9 µM (1:2 serial dilutions).
Figures 4a, b shows dose-response curves for the tested compounds. IC 50 values for compound 1 and AMP-PCP were calculated at 277 µM and 177 µM, respectively. The IC 50 value for compound 1 is very close to the previously described value. However, different substrate concentrations and different buffers (pH) were used in both assays, and therefore IC 50 values cannot be compared directly.
When compared to the MurC and MurF, AMP-PCP is only a weak inhibitor of MurD. 14, 28, 30 Considering that AMP-PCP is a competitive inhibitor of ATP for MurD as well, the calculated K I value would be approximately 20-fold higher (K I ≈ 88 µM) than for MurC and MurF, respectively.
HTS of a focused compound library
Despite many efforts, only a few inhibitors of MurD have been discovered up until now, the majority of them in the micromolar range and lacking antibacterial activity. 31 Our extensive virtual screening campaign for MurD inhibitors (details to be published elsewhere) produced a focused compound library of around 1000 possible low molecular weight inhibitors of MurD. These 1000 compounds, which were assayed in our initial low-scale HTS experiment, served as a good evaluation set to assess the assay performance. To assess the suitability of the MurD reaction for a high-throughput format (total volume of 60 µL), we employed Z′ factor plate analyses. The Z factor is a statistical parameter to evaluate the quality or performance of any given HTS assay, and an excellent assay is characterized by a high Z factor (0.5 ≤ Z factor ≤ 1). 24 The Z′ factor, calculated for the plates, monitored at different times of the day, was always above 0.5 (0.53 ± 0.03, n = 4), indicating the robustness of our assay.
We designed a 3-step strategy to screen the compound library in robotic settings. All compounds were first screened at a 20-and 100-µM concentration to obtain the percentage inhibition values in duplicate. Internal controls, consisting of reagents for full reaction and background reaction, were included in each assay plate. In addition, a positive hit control, AMP-PCP (500 µM), was included in each plate. A hit threshold in the HTS was set at >50% inhibition at a 100-µM compound concentration and >30% at a 20-µM compound concentration. Then, the posi tive hits were retested, using the counterscreen assay, to exclude interference with the coupled enzymes. Finally, true hits were characterized by their IC 50 values using 8 concentration points (as described in the Methods).
After the counterscreen assay, 27 compounds proved to be specific inhibitors of MurD ligase. Although this number may look low at first glance, it is actually a promising result because a nearly 3% hit rate represents a considerable success in an HTS campaign of antibacterial targets. 32 Compound 2 is presented here as a new inhibitor of MurD enzyme with an IC 50 value of 105 µM (Fig. 4c) . This IC 50 value is approximately 3-fold lower when compared to the glutamic acid derivative (compound 1), but the mode of inhibition remains to be determined.
CONCLUSION
A novel assay for monitoring the activity of the bacterial enzyme MurD ligase is presented here. The novel assay has been validated by obtaining K M,app values for the substrates and is amenable for HTS and inhibitor profiling. This is the first time that the IC 50 value for AMP-PCP has been determined. In addition, a novel MurD inhibitor belonging to a structural class different to those already published has been discovered.
It has to be noted that our initial aim was not to test a great number of compounds. Rather, we have focused our efforts on developing a robust and reliable assay that would also have the ability to overcome compound-connected issues such as solubility and false positives. Although this assay has been developed for MurD, one of its advantages is that it can be easily transferred to screen other Mur ligases. Furthermore, if desired, the throughput of the assay can be improved by a transfer to a 384-well format and screening at one concentration.
